ERBB2 and breast carcinoma: We developed a novel spatially-resolved method for identifying and quantifying intratumoral heterogeneity using MRI habitats, then used this analysis to identify unique tumor phenotypes with differing responses to treatment in a preclinical model of HER2+ breast cancer.